EUVIMEDEUVIMED entdecken
Open Access

Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma

Ashley Del Dosso, Elizabeth Tadevosyan, James R Berenson

Oncotarget · 2024

DOI: 10.18632/oncotarget.28547 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncotarget, 2024. Verfasst von Ashley Del Dosso und 2 weiteren Autor:innen. Beteiligte Einrichtung: ONCOtherapeutics, West Hollywood, CA 90069, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Janus Kinase Inhibitors, Pyrazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is the most common primary malignancy of the bone marrow. No established curative treatment is currently available for patients diagnosed with MM. In recent years, new and more effective drugs have become available for the treatment of this B-cell malignancy. These new drugs have often been evaluated together and in combination with older agents. However, even these novel combinations eventually become ineffective; and, thus, novel therapeutic approaches are necessary to help overcome resistance to these treatments. Recently, the Janus Kinase (JAK) family of tyrosine kinases, specifically JAK1 and JAK2, has been shown to have a role in the pathogenesis of MM. Preclinical studies have demonstrated a role for JAK signaling in direct and indirect growth of MM and downregulation of anti-tumor immune responses in these patients. Also, inhibition of JAK proteins enhances the anti-MM effects of other drugs used to treat MM. These findings have been confirmed in clinical studies which have further demonstrated the safety and efficacy of JAK inhibition as a means to overcome resistance to currently available anti-MM therapies. Additional studies will provide further support for this promising new therapeutic approach for treating patients with MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaJanus Kinase InhibitorsPyrazolesHumansPyrimidinesNitrilesJanus KinasesJanus Kinase 2Janus Kinase 1Protein Kinase Inhibitors

Stichwörter der Autor:innen

JAK/STATclinical trialcytokinemultiple myelomaruxolitinib

Substanzen

ruxolitinibJanus Kinase InhibitorsPyrimidinesNitrilesJanus KinasesJanus Kinase 2Janus Kinase 1Protein Kinase InhibitorsPyrazoles

Autor:innen und Institutionen

  • ONCOtherapeutics, West Hollywood, CA 90069, USA.
  • Berenson Cancer Center, West Hollywood, CA 90069, USA.
  • Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA.

Zitieren

APA

Del Dosso, A., Tadevosyan, E., & Berenson, J. R. (2024). Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma. Oncotarget. https://doi.org/10.18632/oncotarget.28547

Vancouver

Del Dosso A, Tadevosyan E, Berenson JR. Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma. Oncotarget. 2024. doi:10.18632/oncotarget.28547

BibTeX
@article{DelDosso2024,
  author = {Del Dosso, Ashley and Tadevosyan, Elizabeth and Berenson, James R},
  title = {Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma},
  journal = {Oncotarget},
  year = {2024},
  doi = {10.18632/oncotarget.28547}
}
Kostenlos starten →